These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8111303)

  • 21. Modeling and simulation in molecular pharmacology.
    Mihalas GI; Kygyosi A; Lungeanu D; Vernic C
    Stud Health Technol Inform; 1998; 52 Pt 1():372-5. PubMed ID: 10384481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments?
    Jonker DM; Voskuyl RA; Danhof M
    Epilepsia; 2007 Mar; 48(3):412-34. PubMed ID: 17346245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An overview of some pharmacological methods used in safety pharmacology studies.
    Pugsley MK
    Proc West Pharmacol Soc; 2004; 47():18-22. PubMed ID: 15633602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The use of imaging techniques in drug research].
    Syvälahti E; Hietala J
    Duodecim; 1998; 114(10):1019-26. PubMed ID: 11524776
    [No Abstract]   [Full Text] [Related]  

  • 25. Analysis of drug interactions in combined drug therapy by reflection method.
    Zheng QS; Sun RY
    Acta Pharmacol Sin; 2000 Feb; 21(2):183-7. PubMed ID: 11263269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular change signal-to-noise criteria for interpreting experiments involving exposure of biological systems to weakly interacting electromagnetic fields.
    Vaughan TE; Weaver JC
    Bioelectromagnetics; 2005 May; 26(4):305-22. PubMed ID: 15832332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An application of Ito's lemma in population pharmacokinetics and pharmacodynamics.
    Ramanathan M
    Pharm Res; 1999 Apr; 16(4):584-6. PubMed ID: 10227716
    [No Abstract]   [Full Text] [Related]  

  • 28. A method for estimating pharmacokinetic risks of concentration-dependent drug interactions from preclinical data.
    Ramanathan M
    Drug Metab Dispos; 1999 Dec; 27(12):1479-87. PubMed ID: 10570030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Mathematical calculations for determining the concentration-time dependence in toxicological research].
    Kiselev AV
    Gig Sanit; 1983 Jul; (7):40-1. PubMed ID: 6618221
    [No Abstract]   [Full Text] [Related]  

  • 30. Modeling promiscuity based on in vitro safety pharmacology profiling data.
    Azzaoui K; Hamon J; Faller B; Whitebread S; Jacoby E; Bender A; Jenkins JL; Urban L
    ChemMedChem; 2007 Jun; 2(6):874-80. PubMed ID: 17492703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The time to move cytochrome p450 induction into mainstream pharmacology is long overdue.
    Smith DA; Dickins M; Fahmi OA; Iwasaki K; Lee C; Obach RS; Padbury G; De Morais SM; Ripp SL; Stevens J; Voorman R; Youdim K
    Drug Metab Dispos; 2007 Apr; 35(4):697-8. PubMed ID: 17384203
    [No Abstract]   [Full Text] [Related]  

  • 32. Connection of pharmacokinetics and pharmacodynamics--how does it work?
    Cawello W
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):414-7. PubMed ID: 9352389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Globalization of quantitative pharmacology: first international symposium of quantitative pharmacology in drug development and regulation.
    Barrett JS; Shi J; Xie HT; Huang XH; Fossler MJ; Sun RY
    J Clin Pharmacol; 2008 Jul; 48(7):787-92. PubMed ID: 18490494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action.
    Ganter B; Tugendreich S; Pearson CI; Ayanoglu E; Baumhueter S; Bostian KA; Brady L; Browne LJ; Calvin JT; Day GJ; Breckenridge N; Dunlea S; Eynon BP; Furness LM; Ferng J; Fielden MR; Fujimoto SY; Gong L; Hu C; Idury R; Judo MS; Kolaja KL; Lee MD; McSorley C; Minor JM; Nair RV; Natsoulis G; Nguyen P; Nicholson SM; Pham H; Roter AH; Sun D; Tan S; Thode S; Tolley AM; Vladimirova A; Yang J; Zhou Z; Jarnagin K
    J Biotechnol; 2005 Sep; 119(3):219-44. PubMed ID: 16005536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A model for the interaction of two chemicals.
    Sen P; Bell D
    J Theor Biol; 2006 Feb; 238(3):652-6. PubMed ID: 16061259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A program for the optimum design of pharmacokinetic, pharmacodynamic, drug metabolism and drug-drug interaction models.
    Graham G; Gueorguieva I; Dickens K
    Comput Methods Programs Biomed; 2005 Jun; 78(3):237-49. PubMed ID: 15899308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "All possible steps" approach to the accelerated use of Gillespie's algorithm.
    Lipshtat A
    J Chem Phys; 2007 May; 126(18):184103. PubMed ID: 17508788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experimental and mathematical modeling methods for the investigation of toxicological interactions.
    El-Masri HA
    Toxicol Appl Pharmacol; 2007 Sep; 223(2):148-54. PubMed ID: 16996550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noncompartmental methods of drug characterization: statistical moment theory.
    Martinez MN
    J Am Vet Med Assoc; 1998 Oct; 213(7):974-80. PubMed ID: 9776992
    [No Abstract]   [Full Text] [Related]  

  • 40. The failure of dose-response models to predict low dose effects: a major challenge for biomedical, toxicological and aging research.
    Calabrese EJ
    Biogerontology; 2006 Apr; 7(2):119-22. PubMed ID: 16802115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.